AVANOS MEDICAL, INC. reported financial results for the three months ended March 31, 2026.
“On May 5, 2026, Avanos Medical, Inc. issued a press release announcing its results of operations for the three months ended March 31, 2026.”
AVANOS MEDICAL, INC. — fact timeline
Source-grounded facts extracted from AVANOS MEDICAL, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
AVANOS MEDICAL, INC. entered into Agreement and Plan of Merger with A-AV Holdco I, Inc. and A-AV MergerSub, Inc. valued at $25.00 per Share in cash (effective 2026-04-13).
“On April 13, 2026, Avanos Medical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, A-AV Holdco I, Inc., a Delaware corporation (“Parent”), and A-AV MergerSub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Subsidiary”).”
Michael C. Greiner departed as other_named_officer at AVANOS MEDICAL, INC..
“On April 28, 2025, Avanos Medical, Inc. (the “Company”) and Michael C. Greiner entered into a Separation and Consulting Agreement (the “Separation and Consulting Agreement”).”
Warren J. Machan departed as Interim Chief Financial Officer at AVANOS MEDICAL, INC..
“Mr. Machan no longer serves as the Company’s Interim Chief Financial Officer effective April 14, 2025”
Jason M. Pickett was appointed as Interim Chief Financial Officer and Treasurer at AVANOS MEDICAL, INC..
“The Company has appointed Jason M. Pickett as Interim Chief Financial Officer and Treasurer, effective April 14, 2025.”
Michael C. Greiner departed as Senior Vice President, Chief Financial Officer and Chief Transformation Officer at AVANOS MEDICAL, INC..
“On April 18, 2025, Michael C. Greiner announced that he will leave the Company to pursue other opportunities because the Company did not offer him a position comparable to the one he held prior to his role as the Company’s Interim Chief Executive Officer.”
Jason M. Pickett was appointed as Interim Chief Financial Officer and Treasurer at AVANOS MEDICAL, INC..
“The Company has appointed Jason M. Pickett as Interim Chief Financial Officer and Treasurer, effective April 14, 2025.”
Warren J. Machan departed as Interim Chief Financial Officer at AVANOS MEDICAL, INC..
“Mr. Machan no longer serves as the Company’s Interim Chief Financial Officer effective April 14, 2025”
Michael C. Greiner departed as Senior Vice President and Chief Financial Officer at AVANOS MEDICAL, INC..
“On April 18, 2025, Michael C. Greiner announced that he will leave Avanos Medical, Inc. (the “Company”) to pursue other opportunities because the Company did not offer him a position comparable to the one he held prior to his role as the Company’s Interim Chief Executive Officer.”
David Pacitti was appointed as Chief Executive Officer at AVANOS MEDICAL, INC..
“On March 17, 2025, Avanos Medical, Inc. (the “Company”) announced the appointment of David Pacitti as the Company’s Chief Executive Officer, effective April 14, 2025.”
David Pacitti was appointed as Chief Executive Officer at AVANOS MEDICAL, INC..
“On March 17, 2025, Avanos Medical, Inc. (the “Company”) announced the appointment of David Pacitti as the Company’s Chief Executive Officer, effective April 14, 2025.”
Michael C. Greiner was appointed as Interim Chief Executive Officer at AVANOS MEDICAL, INC..
“the Company appointed Michael C. Greiner to serve as Interim Chief Executive Officer of the Company.”
Joseph F. Woody retired as Chief Executive Officer at AVANOS MEDICAL, INC..
“On October 28, 2024, the Company announced the retirement of Joseph F. Woody as Chief Executive Officer and a member of the Board of Directors of the Company, effective immediately.”
Indrani Franchini was appointed as Director at AVANOS MEDICAL, INC..
“On June 28, 2024, the Board of Directors (the “Board”) of Avanos Medical, Inc. (the “Company”) appointed Indrani Franchini to the Board, effective July 1, 2024.”
AVANOS MEDICAL, INC. reported financial results for three months ended March 31, 2024.
“On May 2, 2024, Avanos Medical, Inc. (the "Company") issued a press release announcing its results of operations for the three months ended March 31, 2024.”
AVANOS MEDICAL, INC. shareholders approved To approve, on an advisory basis, the compensation of the Company’s named executive officers at the 2024-04-25 meeting.
“The votes cast on Proposal No. 3 were as follows: For Against Abstain Broker non-votes Approval of NEO compensation 38,515,084 2,104,432 57,555 2,312,795”
AVANOS MEDICAL, INC. shareholders approved To ratify the appointment of Deloitte & Touche LLP as the Company’s independent auditors for 2024 at the 2024-04-25 meeting.
“The votes cast on Proposal No. 2 were as follows: For Against Abstain Appointment of Deloitte & Touche LLP 42,503,768 435,813 50,285”
AVANOS MEDICAL, INC. shareholders approved To elect Gary D. Blackford, Dr. Lisa Egbuonu-Davis, Patrick J. O’Leary, Dr. Julie Shimer and Joseph F. Woody to serve one-year terms expiring at the 2025 Annual Meeting of Stockholders at the 2024-04-25 meeting.
“The votes cast on Proposal No. 1 were as follows: Director For Withhold Broker non-votes Gary D. Blackford 39,916,596 760,475 2,312,795 Dr. Lisa Egbuonu-Davis 39,845,016 832,055 2,312,795 Patrick J. O’Leary 40,149,326 527,745 2,312,795 Dr. Julie Shimer 39,726,238 950,833 2,312,795 Joseph F. Woody 40,385,119 291,952 2,312,795”
AVANOS MEDICAL, INC. reported fourth quarter and full-year 2023 results: revenue Fourth quarter net sales from continuing operations totaled $173.3 million, a 4.6% decrease from the prior year. For the, EPS Fourth quarter diluted earnings per share from continuing operations were $0.24 compared to diluted earnings per share o.
“Fourth quarter net sales from continuing operations totaled $173.3 million, a 4.6% decrease from the prior year. For the full-year, net sales from continuing operations decreased 1.6% to $673.3 million. • Fourth quarter diluted earnings per share from continuing operations were $0.24 compared to diluted earnings per share of $0.21 per share a year ago, and fourth quarter adjusted diluted earnings per share from continuing operations were $0.36 compared to $0.45 in the prior year. 2023 full-year diluted loss per share from continuing operations were $0.21 compared to diluted earnings per share of $0.46 in the prior year, and adjusted diluted earnings per share from continuing operations were $1.03 compared to $1.00 in 2022.”
AVANOS MEDICAL, INC. reported preliminary financial results for the quarter and full-year ended December 31, 2023.
“On January 4, 2024, Avanos Medical, Inc. (the “Company”) issued a press release that announced selected, unaudited preliminary financial results for the quarter and full-year ended December 31, 2023.”
AVANOS MEDICAL, INC. reported financial results for the three and nine months ended September 30, 2023.
“Avanos Medical, Inc. (the “Company”) announced its results of operations for the three and nine months ended September 30, 2023 in a press release dated November 1, 2023.”
AVANOS MEDICAL, INC. completed a disposition involving SunMed Group Holdings, LLC for $110 million in cash (closed 2023-10-02).
“Health (“RH”) business (the “Divestiture”). In accordance with the Amended Purchase Agreement, the total purchase price paid by Buyer in connection with the Divestiture was $110 million in cash at the closing, subject to certain adjustments as provided in the Amended Purchase Agreement based on the indebtedness and inventory transferred to Buyer at the closing”
AVANOS MEDICAL, INC. reported financial results for the three and six months ended June 30, 2023.
“Avanos Medical, Inc. (the “Company”) announced its results of operations for the three and six months ended June 30, 2023 in a press release dated August 9, 2023.”
AVANOS MEDICAL, INC. entered into Purchase Agreement with SunMed Group Holdings, LLC valued at $110 million (effective 2023-06-07).
“On June 7, 2023, Avanos Medical, Inc. (the “Company”), entered into a Purchase Agreement (the “Purchase Agreement”) by and among the Company and certain of its affiliates and SunMed Group Holdings, LLC (“Buyer”).”
AVANOS MEDICAL, INC. reported financial results for the three months ended March 31, 2023.
“Avanos Medical, Inc. (the “Company”) announced its results of operations for the three months ended March 31, 2023 in a press release dated May 3, 2023.”
AVANOS MEDICAL, INC. shareholders approved Approve an amendment to the Company’s 2021 Long Term Incentive Plan to increase the number of shares reserved for issuance at the 2023-04-27 meeting.
“The votes cast on Proposal No. 4 were as follows: For Against Abstain Broker non-votes Amendment of the 2021 Long Term Incentive Plan 39,961,025 1,585,386 112,920 2,256,780”
AVANOS MEDICAL, INC. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2023-04-27 meeting.
“The votes cast on Proposal No. 3 were as follows: For Against Abstain Broker non-votes Approval of NEO compensation 38,956,746 2,593,580 109,005 2,256,780”
AVANOS MEDICAL, INC. shareholders approved Ratify the appointment of Deloitte & Touche LLP as the Company’s independent auditors for 2023 at the 2023-04-27 meeting.
“The votes cast on Proposal No. 2 were as follows: For Against Abstain Appointment of Deloitte & Touche LLP 43,502,269 268,752 145,090”
AVANOS MEDICAL, INC. shareholders approved Election of directors at the 2023-04-27 meeting.
“The votes cast on Proposal No. 1 were as follows: Director For Withhold Broker non-votes Gary D. Blackford 40,939,693 719,638 2,256,780 John P. Byrnes 41,020,988 638,343 2,256,780 Dr. Lisa Egbuonu-Davis 41,187,183 472,148 2,256,780 Patrick J. O’Leary 41,327,319 332,012 2,256,780 Dr. Julie Shimer 35,455,820 6,203,511 2,256,780 Joseph F. Woody 41,422,567 236,764 2,256,780”
Dr. Lisa Egbuonu-Davis was appointed as Director at AVANOS MEDICAL, INC..
“On February 28, 2023, the Board of Directors (the “Board”) of Avanos Medical, Inc. (the “Company”) appointed Dr. Lisa Egbuonu-Davis to the Board, effective March 6, 2023.”
AVANOS MEDICAL, INC. reported financial results for the three months and year ended December 31, 2022.
“The Company announced its results of operations for the three months and year ended December 31, 2022 in a press release dated February 21, 2023 that is attached and incorporated herein by reference as Exhibit 99.1.”
AVANOS MEDICAL, INC. announced a restructuring with charges of between $20.0 million and $25.0 million affecting Chronic Care and Pain franchises (between $6.0 million and $8.0 million of employee severance and benefits costs).
“The Company now estimates it will incur between $20.0 million and $25.0 million of cash expenses in connection with the Transformation Process, consisting of between $9.0 million and $12.0 million of program management consulting and employee retention expenses; between $8.0 million and $11.0 million of expenses associated with manufacturing and supply chain improvements and portfolio rationalization; and the remainder for expenses associated with organizational design and alignment and other related activities.”
Arjun R. Sarker resigned as Senior Vice President – International at AVANOS MEDICAL, INC..
“On February 14, 2023, Arjun R. Sarker, the Company’s Senior Vice President – International, notified the Company that he will resign from his position with the Company, effective May 10, 2023.”
AVANOS MEDICAL, INC. announced a restructuring affecting Chronic Care and Pain franchises combined into single commercial organization; exit certain low-margin, low-growth product categories.
“On January 10, 2023, Avanos Medical, Inc. (the “Company”) approved a three-year transformation process (the “Transformation Process”) pursuant to which the Company plans to: (i) combine its Chronic Care and Pain franchises into a single commercial organization focused on the Digestive Health and Orthopedic Pain & Recovery product categories; (ii) exit certain low-margin, low-growth product categories, including through targeted divestitures; (iii) undertake additional cost management activities to enhance the Company’s operating profitability; and (iv) pursue efficient capital allocation strategies, including through acquisitions that meet the Company’s strategic and financial criteria.”
William D. Haydon was terminated as Senior Vice President and General Manager, Pain Franchise at AVANOS MEDICAL, INC..
“On January 10, 2023, the Company and William D. Haydon, the Company’s Senior Vice President and General Manager, Pain Franchise, entered into a Severance and Separation Agreement (the “Severance and Separation Agreement”) pursuant to which: (i) Mr. Haydon’s employment with the Company will terminate effective March 31, 2023 (the “Separation Date”);”
AVANOS MEDICAL, INC. reported financial results for the three months ended September 30, 2022.
“Avanos Medical, Inc. (the “Company”) announced its results of operations for the three months ended September 30, 2022 in a press release dated November 2, 2022.”
Maria Sainz resigned as Director at AVANOS MEDICAL, INC..
“On October 7, 2022, Maria Sainz, a member of the Board of Directors (the “Board”) of Avanos Medical, Inc. (the “Company”), notified the Company of her intention to resign from the Board, effective January 1, 2023.”
David E. Ball departed as Senior Vice President, Global Supply Chain & Procurement at AVANOS MEDICAL, INC..
“On May 19, 2022, David E. Ball, the Senior Vice President, Global Supply Chain & Procurement of Avanos Medical, Inc. (the “Company”), provided notice of his intention to retire from the Company.”
John J. Hurley was appointed as Principal Accounting Officer at AVANOS MEDICAL, INC..
“On April 28, 2022, the Company appointed John J. Hurley, age 51, as its Principal Accounting Officer.”
Michael C. Greiner was appointed as principal accounting officer at AVANOS MEDICAL, INC..
“The Company has appointed Michael C. Greiner as principal accounting officer, effective as of October 22, 2021.”
Renato Negro resigned as Chief Accounting Officer at AVANOS MEDICAL, INC..
“Renato Negro notified the Company that he is resigning from his position as Chief Accounting Officer, effective as of October 22, 2021.”
Heidi Kunz resigned as Director at AVANOS MEDICAL, INC..
“On July 29, 2021, Heidi Kunz notified the Company that she was resigning from the Board of Directors to pursue other business opportunities.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.